![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » German Devicemaker Gets CE-IVD Mark for Lung Cancer Assay
German Devicemaker Gets CE-IVD Mark for Lung Cancer Assay
![EU_Flag_pic.png](https://www.fdanews.com/ext/resources/test/Drug-Images3/EU_Flag_pic.png?t=1580334888&width=430)
December 21, 2017
Epigenomics, a Germany-based molecular diagnostics company, received the CE-IVD mark for its blood-based lung cancer test Epi proLung.
The device includes the company’s proprietary DNA methylation biomarkers.
The European Commission provided funding for the development of the assay, the company said.
Upcoming Events
-
21Oct